Showing results (111-120 of 125) with videos related to
Sort By:
Pageof 13
Molecular Cancer Therapeutics|April 19, 2024
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus RecommendationsFunda Meric-Bernstam, Michael W Lloyd, Soner Koc, et al.Molecular Cancer Therapeutics|July 15, 2026
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor CombinationsAnh Minh Tran Huynh, Jonathan T Lei, Rachel Brough, et al.Nature Medicine|March 27, 2018
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancerAmritha Nair, Hsiang-Ching Chung, Tingting Sun, et al.Biorxiv : the Preprint Server for Biology|December 23, 2024
Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy ResponsesJonathan T Lei, Lacey E Dobrolecki, Chen Huang, et al.Cancer Discovery|August 24, 2022
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Eric J Jaehnig, Karsten Krug, et al.Cell|January 15, 2021
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancerElizabeth A Bowling, Jarey H Wang, Fade Gong, et al.NAR Cancer|April 27, 2022
PDXNet portal: patient-derived Xenograft model, data, workflow and tool discoverySoner Koc, Michael W Lloyd, Jeffrey W Grover, et al.Nature Cancer|February 28, 2022
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncologyKatrin P Guillen, Maihi Fujita, Andrew J Butterfield, et al.Cell|October 17, 2024
IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancerLongyong Xu, Fanglue Peng, Qin Luo, et al.Nature|May 18, 2022
PHGDH heterogeneity potentiates cancer cell dissemination and metastasisMatteo Rossi, Patricia Altea-Manzano, Margherita Demicco, et al.Pageof 13